Full Press Release Details
linvoseltamab bla for treatment of relapsed refractory multiple myeloma accepted for fda priority review.
REGN
linvoseltamab bla for treatment of relapsed refractory multiple myeloma accepted for fda priority review
Key Takeaway: linvoseltamab bla for treatment of relapsed refractory multiple myeloma accepted for fda priority review